Login / Signup

Manufacturing of hybrid drug delivery systems by utilizing the fused filament fabrication (FFF) technology.

Georgios K EleftheriadisChristos S KatsiotisNatalja GeninaJohan BoetkerJukka RantanenDimitrios G Fatouros
Published in: Expert opinion on drug delivery (2020)
The potential of fused filament fabrication (FFF) for the administration of active pharmaceutical compounds is a recent approach to develop complex and custom-made drug delivery systems (DDSs). However, the FFF technology is characterized by certain limitations, which are associated with the nature of the process, i.e., the required mechanical properties of the feedstock, as well as the thermal stability of the incorporated polymers, excipients and active compounds. Thus, hybrid DDSs have been recently introduced, to overcome these boundaries. The concept of these systems is defined by the effective coupling of FFF with conventional manufacturing technologies, as a novel pathway to expand the available pool of raw materials and pharmaceutical applications of FFF.
Keyphrases
  • human health
  • risk assessment
  • climate change